CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study
- PMID: 20147814
- DOI: 10.1097/ID.0b013e3181cec8bc
CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study
Abstract
Biochemical markers of bone metabolism have been used in medicine to evaluate and provide treatment to patients with metabolic bone diseases, such as osteoporosis. Serum cross-linked C-telopeptide of type I collagen (CTX) is a marker of osteoclast activity and is used to assess the level of bone resorption. Recently, in oral and maxillofacial surgery, it was proposed that the levels of serum CTX may predict the subsequent risk of developing osteonecrosis of the jaws (ONJ) after oral surgery procedures for patients taking oral bisphosphonates (BPs). The goal of this study was to determine whether this specific serum marker of bone resorption could preoperatively predict the risk of developing ONJ from oral BPs.We hypothesized that there is no clinical correlation between the observed preoperative serum CTX values and the risk of developing ONJ. The authors examine the scientific basis (validity) of the morning fasting serum CTX test in 163 consecutive patients who underwent various oral surgery procedures in the office. The authors also review the laboratory test results and the recommended protocol based on the test values. One hundred sixty-three patients (mean age, 75.9 years) were divided into 2 groups. Group I was the control group that consisted of 109 patients taking oral BPs who did not take the CTX test preoperatively. Group 2 consisted of 54 patients taking BPs and who elected to have the CTX test performed to assess their level of risk of developing ONJ, preoperatively. Both groups of patients were observed for a period of 8 weeks for signs and symptoms of BP-associated ONJ after surgery. The clinical data at 8 weeks and beyond revealed that there was no evidence of BP-associated ONJ in all participants. We conclude that the serum CTX is not a valid preoperative test to accurately assess the level of risk of developing ONJ and is not indicated in the oral surgery patient.
Similar articles
-
CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.Implant Dent. 2009 Dec;18(6):492-500. doi: 10.1097/ID.0b013e3181c6837c. Implant Dent. 2009. PMID: 20009603 Review.
-
Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.J Oral Maxillofac Surg. 2010 Sep;68(9):2241-7. doi: 10.1016/j.joms.2010.05.043. J Oral Maxillofac Surg. 2010. PMID: 20728033
-
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410. doi: 10.1016/j.joms.2007.08.003. J Oral Maxillofac Surg. 2007. PMID: 18022461
-
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.J Oral Maxillofac Surg. 2009 Jun;67(6):1167-73. doi: 10.1016/j.joms.2009.02.004. J Oral Maxillofac Surg. 2009. PMID: 19446200 Clinical Trial.
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
Cited by
-
Immediate implant placement following 1-year treatment with oral versus intravenous bisphosphonates: a histomorphometric canine study on peri-implant bone.Clin Oral Investig. 2019 Apr;23(4):1803-1809. doi: 10.1007/s00784-018-2579-7. Epub 2018 Sep 5. Clin Oral Investig. 2019. PMID: 30187256
-
Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.Biomed Res Int. 2020 Oct 15;2020:5847429. doi: 10.1155/2020/5847429. eCollection 2020. Biomed Res Int. 2020. PMID: 33123580 Free PMC article. Clinical Trial.
-
Comparison of BALP, CTX-I, and IL-4 levels around miniscrew implants during orthodontic tooth movement between two different amounts of force.Angle Orthod. 2019 Jul;89(4):630-636. doi: 10.2319/071718-520.1. Epub 2019 Feb 7. Angle Orthod. 2019. PMID: 30730198 Free PMC article.
-
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].Wien Med Wochenschr. 2016 Feb;166(1-2):68-74. doi: 10.1007/s10354-016-0437-2. Wien Med Wochenschr. 2016. PMID: 26847441 German.
-
Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).Clin Oral Investig. 2016 May;20(4):753-8. doi: 10.1007/s00784-015-1563-8. Epub 2015 Aug 26. Clin Oral Investig. 2016. PMID: 26307268
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical